Shares of Imunon, Inc. (NASDAQ:IMNN – Get Rating) traded down 2.8% on Thursday . The company traded as low as $1.38 and last traded at $1.38. 20,449 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 124,634 shares. The stock had previously closed at $1.42.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on the company. Brookline Capital Management reiterated a "buy" rating on shares of Imunon in a research report on Monday, November 14th. Alliance Global Partners assumed coverage on Imunon in a research report on Thursday, October 13th. They issued a "buy" rating and a $15.00 price objective on the stock.
Get
Imunon alerts:
Imunon Stock Down 2.8 %
The company has a debt-to-equity ratio of 0.13, a current ratio of 4.75 and a quick ratio of 4.75. The business has a fifty day simple moving average of $1.51.
Imunon (NASDAQ:IMNN – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.06). Imunon had a negative return on equity of 56.47% and a negative net
margin of 5,377.20%. The business had revenue of $0.13 million during the quarter, compared to analysts' expectations of $0.11 million. On average, sell-side analysts anticipate that Imunon, Inc. will post -4.14 EPS for the current fiscal year.
Imunon Company Profile
(Get Rating)
Imunon, Inc, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.
Read More
- Get a free copy of the StockNews.com research report on Imunon (IMNN)
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
